Eyefinity vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Optometry and optical PMS owned by VSP Global, serving independent eyecare practices across the US. Rancho Cordova CA; OfficeMate covers scheduling, billing, and EHR; iMedicWare handles optical point-of-sale and lab orders;
About
Eyefinity is a Rancho Cordova, California-based optometry and optical practice management software company owned by VSP Global, the largest vision care benefits plan in the United States. Eyefinity provides practice management, electronic health records, and optical lab connectivity tools specifically designed for independent optometrists and optician-led optical retail businesses. The company's products include OfficeMate for practice scheduling, billing, and medical records; ExamWRITER for clinical charting and electronic prescriptions; and iMedicWare for optical point-of-sale and lab order management. Eyefinity's products are used by tens of thousands of eye care professionals across the U.S., many of whom are part of the VSP network of independent optometrists.\n\nEyefinity's connection to VSP Global gives it several advantages in the independent optometry market. VSP's vision care network includes a large proportion of independent optometrists who are naturally inclined toward Eyefinity software because of the seamless VSP insurance eligibility verification and claim submission integration that simplifies the billing workflow for VSP patients—which constitute a significant portion of most private-practice optometry patient volumes. This network integration effectively makes Eyefinity the path of least resistance for VSP-affiliated optometrists seeking practice management software, creating a built-in distribution advantage.\n\nEyefinity has been modernizing its product portfolio through cloud-based offerings and improved user interfaces as competitive pressure from newer optometry software entrants increases. The company competes with Compulink Healthcare Solutions, Revolution EHR, and Crystal Practice Management in the optometry practice management market. Eyefinity differentiates on its VSP integration depth, its large installed base in the VSP network, and the operational trust that comes from being backed by the dominant vision care benefits plan in the United States.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.